Community/Retail

The FDA has permitted marketing of a new device intended to treat diabetic foot ulcers.

A look at some of the top read articles on Pharmacy Times from 2017.

Busy pharmacists looking to achieve their health goals for 2018 should look no further than their cell phones.

With the New Year on our heels, let’s look back on some of the most noteworthy FDA approvals of 2017.

Why I included a computer coding aspect into my APPE rotation

What my experience in pharmacy, jazz piano and language studies have in common

Make a commitment to make the workplace a cleaner, happier, and healthier place in 2018.

Abbott has released its newest system for type 1 and 2 diabetes.

This is the first part of a series on how pharmacy professionals have been depicted on TV, both in a positive and negative manner.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Hydroxyurea is indicated to decrease the prevalence of painful crises and the need for transfusions in pediatric patients aged 2 years and older with sickle cell anemia with moderate-to-severe painful crises.

The FDA recently approved nivolumab (Opdivo) for the treatment of patients with melanoma whose disease has spread to the lymph nodes or those with metastatic disease who have undergone resection, according to a press release.

Officials with the FDA recently approved cabozantinib (Cabometyx) for the first-line treatment of patients with advanced renal cell carcinoma (RCC), according to a press release.

Officials with the FDA granted accelerated approval to bosutinib (Bosulif) for the treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).

Now that Eli Lilly is looking to create a closed-loop system for diabetes management, does that mean this product will soon be available?

Negative interactions with doctors' offices can have serious consequences, so play nice.

We explore what happened and talk to CVS corporate to get their take.

Officials with the FDA have approved angiotensin II (Giapreza, La Jolla Pharmaceutical Company) injection for intravenous infusion to treat dangerously low blood pressure in adults with septic or other distributive shock.

The results of all trials showed that the use of LABA with ICS does not significantly increase the risk of serious asthma outcomes compared to ICS alone.

Officials with the FDA have approved pertuzumab (Perjeta, Roche) in combination with trastuzumab and chemotherapy as an adjuvant therapy for patients with early-stage human epidermal growth factor receptor 2 positive (HER2+) breast cancer who are at high risk of experiencing recurrence.

The cornerstone of working with patients is sharing decision-making and presenting information in a way that helps patients understand the risks and benefits of various choices.

Health care providers can administer egg-based influenza vaccines to people with egg allergy without taking precautions, according to a newly-updated influenza vaccine practice parameter from the Influenza Vaccine and Egg Allergy Practice Parameter Workgroup commissioned by Joint Task Force on Practice Parameters (JTFPP).

Danielle McDonald, PharmD, talks about her residency at Rutgers, the State University of New Jersey.

Rattlesnake pills have received media attention due to their link with Salmonella infection.

HMG-CoA reductase inhibitors are a class of lipid-lowering medications. Here is a look at guidelines and studies for health care professionals.

Officials with the FDA have approved ertugliflozin (Steglatro, Merck and Pfizer) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Officials with the FDA have finalized a rule that bans 24 active ingredients, including triclosan, from being marketed and sold in OTC health care antiseptic products.

Ready to achieve big goals in the new year? Here is how to avoid common pitfalls.